- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
International Journal of Peptides
Volume 2010 (2010), Article ID 460549, 5 pages
Ghrelin's Roles in Stress, Mood, and Anxiety Regulation
1Divisions of Hypothalamic Research and Endocrinology & Metabolism, Department of Internal Medicine, The University of Texas, Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390-9077, USA
2Department of Psychiatry, The University of Texas, Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390-9077, USA
Received 5 October 2009; Accepted 16 December 2009
Academic Editor: Serguei Fetissov
Copyright © 2010 Jen-Chieh Chuang and Jeffrey M. Zigman. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Several studies suggest that the peptide hormone ghrelin mediates some of the usual behavioral responses to acute and chronic stress. Circulating ghrelin levels have been found to rise following stress. It has been proposed that this elevated ghrelin helps animals cope with stress by generating antidepressant-like behavioral adaptations, although another study suggests that decreasing CNS ghrelin expression has antidepressant-like effects. Ghrelin also seems to have effects on anxiety, although these have been shown to be alternatively anxiogenic or anxiolytic. The current review discusses our current understanding of ghrelin's roles in stress, mood, and anxiety.
Metabolic syndrome and psychiatric disorders have become leading threats to the public health worldwide, and associations between the two now have been reported in several studies. For instance, a growing body of literature indicates that obesity is an important environmental risk factor for developing affective disorders. As an example, in a large cross sectional epidemiological U.S. study, a body mass index 30 was found to be associated with a 25% higher rate of mood disorders [1, 2]. Conversely, other studies suggest that psychological stress can increase the risk of developing obesity. For instance, a longitudinal study found that major depression in late adolescent girls was associated with a 2.3-fold increased risk of obesity in adulthood . Also, a chart review of U.S. veterans with posttraumatic stress disorder showed a significantly increased rate of obesity . Thus, it seems likely that certain circulating hormones and critical neuroanatomical circuits exist that regulate both energy homeostasis and our psychological state. Work from a handful of laboratories now suggests that the peptide hormone ghrelin is one such mediator of both behaviors linked to food intake and body weight and behaviors associated with psychosocial stress, mood, and anxiety.
2. Changes in Ghrelin Associated withPsychosocial Stress
We and others have found that rises in ghrelin occur not only in response to states of energy insufficiency [5–8] but also following stress  (Figure 1). For example, elevations in either gastric ghrelin mRNA or total plasma ghrelin have been observed in response to various models of acute stress, including following a tail pinch stress protocol in ddy mice and following a water avoidance stress protocol in Wistar Kyoto and Sprague-Dawley rat [10, 11]. Also, rises in desacyl and acylated ghrelin plasma levels, preproghrelin mRNA levels, and numbers of ghrelin cells were shown in Wistar rats following 5 days continuous exposure to 2 cm of water . Our own study found that acylated ghrelin levels rise in C57BL6/J mice in response to chronic social defeat stress (CSDS); in particular, ghrelin was significantly elevated on the day following the 10-day CSDS protocol and remained elevated when assessed again one month later . In addition, human subjects subjected acutely to psychosocial stress also display increased plasma ghrelin . Supportively, epinephrine, which increases with stress, can increase circulating ghrelin levels .
3. Ghrelin’s Role in Mood
The effects of these stress-induced increases in ghrelin likely include effects on metabolism-related physiology and behavior as well as effects on mood. Our own work using mouse models has revealed that increasing circulating ghrelin levels by 10 days of calorie restriction or by acute s.c. injection produces antidepressant-like responses in the forced swim test . However, caloric restriction no longer induced these responses in mice lacking ghrelin receptors (GHSR-null mice), thus suggesting that interference with ghrelin signaling negates the antidepressant-like behaviors associated with calorie restriction . Also, upon challenge with the CSDS protocol, GHSR-null mice manifested greater social isolation (another marker of depressive-like behavior) than did wild-type littermates . Thus, it has been suggested that activation of ghrelin signaling pathways in response to chronic stress may be a homeostatic adaptation that helps individuals cope with stress (Figure 1, lower panel).
We are aware of only one other study that examines the effects on mood of manipulations to ghrelin expression . For this latter trial, behaviors were examined in rats subsequent to i.c.v. administration of antisense ghrelin oligonucleotides. Rats receiving the antisense ghrelin DNA exhibited much less immobility in the forced swim test as compared to rats receiving scrambled oligonucleotides, thus suggesting an antidepressant-like effect . Associative studies that examine a ghrelin-mood relationship also exist, including one in which a GHSR polymorphism was found associated with major depressive disorder  and another in which total plasma ghrelin levels were compared among subjects with major depression, schizophrenia, and controls .
It is also important to note that ghrelin now has been shown in a handful of studies to affect reward behavior of various types. For example, ghrelin lowers the threshold dose of cocaine required to establish a conditioned place preference, is required for alcohol reward, and itself can elicit a conditioned place preference [18–20]. Ghrelin also increases neuronal activity in brain reward centers in humans shown images of appealing foods  and has been shown to enhance the rewarding value of high-fat diet when administered to mice . These findings are relevant to the discussion of mood as anhedonia is a major component of most forms of depression and as reward behaviors and mood-related behaviors share many of the same neural circuits (see below) .
4. Ghrelin’s Role in Anxiety
Several groups have investigated ghrelin’s effects on anxiety-like behaviors. Using models identical to those described above, we showed that increasing circulating ghrelin levels by calorie restricting mice for ten days or by acute s.c. administration of ghrelin to C57BL6/J mice produces anxiolytic-like responses in the elevated plus maze . However, when GHSR-null mice were calorie restricted, no longer were these anxiolytic-like behavioral responses observed . Thus, we proposed that ghrelin has anxiolytic-like effects and that ghrelin signaling is required for the anxiolytic-like effects of caloric restriction . Our observations seem to be supported by a report showing that Wistar Kyoto rats, which are thought to display more anxiety-like behaviors than Sprague-Dawley and other rat strains, have lower plasma levels of ghrelin than Sprague-Dawley rats . Furthermore, although stress-induced elevations in circulating ghrelin have been noted in both Wistar Kyoto and Sprague-Dawley rat strains, the magnitude of those elevations was significantly lower in the anxiety-prone Wistar Kyoto animals than in the Sprague-Dawley animals .
These findings of anxiolytic-like effects of raised ghrelin levels differ from the results of several other studies. In one of these studies, i.c.v. or i.p. administration of ghrelin to ddy mice decreased duration of time in and number of entries into the open arms of an elevated plus maze (anxiogenic-like actions) when assessed ten minutes after injection . Another group demonstrated that i.c.v. administration of ghrelin or its direct microinjection into the hippocampus, amygdale, or dorsal raphe nucleus induced anxiety-like behaviors in certain rat strains when assessed 5 minutes later in the elevated plus maze, open field test and step-down/inhibitory avoidance test [25, 26]. Also, i.c.v. administration of antisense ghrelin oligonucleotides induced not only antidepressant-like behaviors but also anxiolytic-like responses in rats . Finally, a recent study demonstrated that i.c.v. administration of ghrelin to chicks can induce anxiogenesis .
The reasons for the varied anxiety-related behavioral responses to changes in ghrelin signaling are not clear, at present (Figure 1, upper versus lower panels). They could potentially be due to differences in dose, route of administration, timing of administration, timing of behavioral test after administration, strain or species, or other experimental details such as handling of animals. Strain-dependent differences in performance in various behavioral tasks, such as the elevated plus maze and forced swim test are not uncommon (as an example, in one study, only one out of four inbred strains of mice exhibited sensitivity to fluoxetine in the forced swim test ). Further studies will be required to sort out how these discrepant anxiety-related animal study findings for ghrelin translate into behavioral effects in humans.
5. Potential Mechanisms by Which Ghrelin Regulates Mood
The mechanisms by which ghrelin affects mood-related behaviors have not yet been fully elucidated, but likely include interaction with its receptors in one or more brain sites critical to mood determination. We have shown that ghrelin’s ability to decrease immobility in the forced swim test is dependent on the presence of orexin , and previous work has demonstrated that the antidepressant-like responses to calorie restriction (which also causes an increase in ghrelin) requires orexin . Both direct and indirect links between ghrelin and orexin exist. The most direct link would involve binding of ghrelin to GHSRs present on orexin neurons. Such would be supported by previous studies demonstrating GHSRs within the lateral hypothalamic area of rat, where orexin-containing neuronal cell bodies exist , as well as those showing that ghrelin can induce action potentials in isolated orexin neurons . Alternatively, ghrelin might indirectly engage the orexin system by targeting neurons at other locations which, in turn, project to the lateral hypothalamic area. For instance, several studies suggest that ghrelin directly engages its receptors on AgRP/NPY neurons of the hypothalamic arcuate nucleus (as reviewed in [32, 33]), which are also known to project to lateral hypothalamic orexin neurons .
Ghrelin’s actions on mood also might involve direct interaction with GHSR-containing neurons that exist within the ventral tegmental area. There is growing evidence for a role of the ventral tegmental area (VTA) and its dopaminergic projections to the nucleus accumbens in mood regulation and depression . These circuits, in addition to related projections from the VTA to the amygdala and limbic regions of neocortex, are particularly involved in motivation, the valuation of rewards, the establishment of reward-associated memories and the ability to experience pleasure; impairment of all of these features prominently in the manifestation of depression [35, 36]. As just one example of VTA involvement in depression, chronic social defeat stress has been shown to be associated with a significant increase in VTA dopamine neuron firing rates . In fact, ghrelin also increases action potential frequency in ventral tegmental area neurons and induces dopamine release into the nucleus accumbens [38–40]. Furthermore, ventral tegmental area microinjection of ghrelin increases food intake while microinjection of a GHSR antagonist into the VTA decreases food intake in response to i.p.-injected ghrelin [38, 41].
A large body of work has identified the hippocampus as being involved in antidepressant efficacy and other aspects of depression, including that associated with stress . Many studies have shown that the hippocampus together with the neocortex mediates cognitive aspects of depression such as memory impairment and feelings of worthlessness, hopelessness, guilt, and suicidality . Also, antidepressant therapy stimulates hippocampal neurogenesis, in a time course that seems consistent with the delayed onset of therapeutic action of antidepressant agents . Of interest, GHSRs are known to be expressed within all regions of the hippocampus [30, 44, 45]. In addition, peripherally administered ghrelin is taken up by and increases spine synapse density within the hippocampus . Ghrelin-deficient mice perform poorly in tests of behavioral memory, while ghrelin administration reverses these deficits . Direct microinjection of ghrelin into the hippocampus dose-dependently increases memory retention . Ghrelin also recently has been shown to stimulate cellular proliferation and differentiation of adult rat hippocampal progenitor cells [47, 48], thus suggesting that ghrelin also might induce hippocampal neurogenesis.
Finally, ghrelin’s action on mood may be mediated through the modulation of brain inflammation. Mounting evidence indicates that inflammation may play a role in psychiatric diseases (as reviewed in [49, 50]). For example, correlative studies have suggested the association between inflammation markers and depressive symptoms . In addition, several studies have shown that administration of cytokine or cytokine inducers such as LPS or vaccine can lead to the development of depressive symptoms, while antiinflammatory therapy generates antidepressant-like effects [52–54]. GHSRs have been found to be expressed in immunocytes  and ghrelin or ghrelin mimetics also have been shown to have immunosuppressive actions via the inhibition of proinflammatory cytokines such as IL1-beta, IL-6, and TNF-alpha [56–59]. Together, these data suggest that the stress-induced elevations in ghrelin may help to alleviate the potential damage that could be caused by inflammation within the brain.
Several groups have now demonstrated that rises in ghrelin occur not only during periods of energy insufficiency but also following either acute or chronic stress. Investigations into the ramifications of these stress-associated ghrelin increases are only in their early stages. Our own work suggests that these raised ghrelin levels may help to minimize the deleterious, depression-like behaviors often associated with stress, but perhaps at the expense of a worsened metabolic profile. Future studies are needed to sort out ghrelin’s effects on anxiety-like behaviors, as these have been shown by different groups to be either anxiogenic or anxiolytic. Certainly, it is crucial that these differences in the proposed action of ghrelin on anxiety-like behaviors be resolved given the impact that they might have on the side-effect profile of any GHSR antagonist in development as an antiobesity or antidiabetes agent. Also, the antidepressant-like actions and possible anxiolytic-like actions of ghrelin potentially might enhance the effectiveness of ghrelin mimetics being considered for the treatment of cachexia or anorexia nervosa. Future studies should also be directed towards determining the mechanisms by which ghrelin acts to have its effects on mood-related and anxiety-related behaviors as well as the pathways responsible for the stress-induced elevations in ghrelin.
This work was supported by grants from the NIH (1K08DK068069-01A2 and 1R01DA024680-01) and the Klarman Family Foundation Grants Program in Eating Disorders Research.
- G. E. Simon, M. Von Korff, K. Saunders, et al., “Association between obesity and psychiatric disorders in the US adult population,” Archives of General Psychiatry, vol. 63, no. 7, pp. 824–830, 2006.
- S. Kloiber, M. Ising, S. Reppermund, et al., “Overweight and obesity affect treatment response in major depression,” Biological Psychiatry, vol. 62, no. 4, pp. 321–326, 2007.
- L. P. Richardson, R. Davis, R. Poulton, et al., “A longitudinal evaluation of adolescent depression and adult obesity,” Archives of Pediatrics and Adolescent Medicine, vol. 157, no. 8, pp. 739–745, 2003.
- W. V. Vieweg, D. A. Julius, J. Benesek, et al., “Posttraumatic stress disorder and body mass index in military veterans. Preliminary findings,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 30, no. 6, pp. 1150–1154, 2006.
- B. Otto, U. Cuntz, E. Fruehauf, et al., “Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa,” European Journal of Endocrinology, vol. 145, no. 5, pp. 669–673, 2001.
- D. E. Cummings, D. S. Weigle, R. S. Frayo, et al., “Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery,” The New England Journal of Medicine, vol. 346, no. 21, pp. 1623–1630, 2002.
- H. J. Leidy, K. A. Dougherty, B. R. Frye, K. M. Duke, and N. I. Williams, “Twenty-four-hour ghrelin is elevated after calorie restriction and exercise training in non-obese women,” Obesity, vol. 15, no. 2, pp. 446–455, 2007.
- O. Gualillo, J. E. Caminos, R. Nogueiras, et al., “Effect of food restriction on ghrelin in normal-cycling female rats and in pregnancy,” Obesity Research, vol. 10, no. 7, pp. 682–687, 2002.
- M. Lutter, I. Sakata, S. Osborne-Lawrence, et al., “The orexigenic hormone ghrelin defends against depressive symptoms of chronic stress,” Nature Neuroscience, vol. 11, no. 7, pp. 752–753, 2008.
- A. Asakawa, A. Inui, T. Kaga, et al., “A role of ghrelin in neuroendocrine and behavioral responses to stress in mice,” Neuroendocrinology, vol. 74, no. 3, pp. 143–147, 2001.
- E. Kristenssson, M. Sundqvist, M. Astin, et al., “Acute psychological stress raises plasma ghrelin in the rat,” Regulatory Peptides, vol. 134, no. 2-3, pp. 114–117, 2006.
- M. Ochi, K. Tominaga, F. Tanaka, et al., “Effect of chronic stress on gastric emptying and plasma ghrelin levels in rats,” Life Sciences, vol. 82, no. 15-16, pp. 862–868, 2008.
- V. Rouach, M. Bloch, N. Rosenberg, et al., “The acute ghrelin response to a psychological stress challenge does not predict the post-stress urge to eat,” Psychoneuroendocrinology, vol. 32, no. 6, pp. 693–702, 2007.
- C. D. de la Cour, P. Norlen, and R. Hakanson, “Secretion of ghrelin from rat stomach ghrelin cells in response to local microinfusion of candidate messenger compounds: a microdialysis study,” Regulatory Peptides, vol. 143, no. 1–3, pp. 118–126, 2007.
- M. Kanehisa, J. Akiyoshi, T. Kitaichi, et al., “Administration of antisense DNA for ghrelin causes an antidepressant and anxiolytic response in rats,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 30, no. 8, pp. 1403–1407, 2006.
- K. Nakashima, J. Akiyoshi, K. Hatano, et al., “Ghrelin gene polymorphism is associated with depression, but not panic disorder,” Psychiatric Genetics, vol. 18, no. 5, p. 257, 2008.
- A. Schanze, U. Reulbach, M. Scheuchenzuber, M. Groschl, J. Kornhuber, and T. Kraus, “Ghrelin and eating disturbances in psychiatric disorders,” Neuropsychobiology, vol. 57, no. 3, pp. 126–130, 2008.
- E. Jerlhag, “Systemic administration of ghrelin induces conditioned place preference and stimulates accumbal dopamine,” Addiction Biology, vol. 13, no. 3-4, pp. 358–363, 2008.
- K. W. Davis, P. J. Wellman, and P. S. Clifford, “Augmented cocaine conditioned place preference in rats pretreated with systemic ghrelin,” Regulatory Peptides, vol. 140, no. 3, pp. 148–152, 2007.
- E. Jerlhag, E. Egecioglu, S. Landgren, et al., “Requirement of central ghrelin signaling for alcohol reward,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 27, pp. 11318–11323, 2009.
- S. Malik, F. McGlone, D. Bedrossian, and A. Dagher, “Ghrelin modulates brain activity in areas that control appetitive behavior,” Cell Metabolism, vol. 7, no. 5, pp. 400–409, 2008.
- M. Perello, I. Sakata, S. Birnbaum, et al., “Ghrelin increases the rewarding value of high fat diet in an orexin-dependent manner,” Biological Psychiatry. In press.
- E. J. Nestler and W. A. Carlezon Jr., “The mesolimbic dopamine reward circuit in depression,” Biological Psychiatry, vol. 59, pp. 1151–1159, 2006.
- E. Kristensson, M. Sundqvist, R. Hakanson, and E. Lindstrom, “High gastrin cell activity and low ghrelin cell activity in high-anxiety Wistar Kyoto rats,” Journal of Endocrinology, vol. 193, no. 2, pp. 245–250, 2007.
- V. P. Carlini, M. E. Monzon, M. M. Varas, et al., “Ghrelin increases anxiety-like behavior and memory retention in rats,” Biochemical and Biophysical Research Communications, vol. 299, no. 5, pp. 739–743, 2002.
- V. P. Carlini, M. M. Varas, A. B. Cragnolini, H. B. Schioth, T. N. Scimonelli, and S. R. de Barioglio, “Differential role of the hippocampus, amygdala, and dorsal raphe nucleus in regulating feeding, memory, and anxiety-like behavioral responses to ghrelin,” Biochemical and Biophysical Research Communications, vol. 313, no. 3, pp. 635–641, 2004.
- P. Carvajal, V. P. Carlini, H. B. Schioth, S. R. de Barioglio, and N. A. Salvatierra, “Central ghrelin increases anxiety in the open field test and impairs retention memory in a passive avoidance task in neonatal chicks,” Neurobiology of Learning and Memory, vol. 91, no. 4, pp. 402–407, 2009.
- S. C. Dulawa, K. A. Holick, B. Gundersen, and R. Hen, “Effects of chronic fluoxetine in animal models of anxiety and depression,” Neuropsychopharmacology, vol. 29, no. 7, pp. 1321–1330, 2004.
- M. Lutter, V. Krishnan, S. J. Russo, S. Jung, C. A. McClung, and E. J. Nestler, “Orexin signaling mediates the antidepressant-like effect of calorie restriction,” Journal of Neuroscience, vol. 28, no. 12, pp. 3071–3075, 2008.
- V. Mitchell, S. Bouret, J. C. Beauvillain, et al., “Comparative distribution of mRNA encoding the growth hormone secretagogue-receptor (GHS-R) in Microcebus murinus (primate, lemurian) and rat forebrain and pituitary,” Journal of Comparative Neurology, vol. 429, no. 3, pp. 469–489, 2001.
- A. Yamanaka, C. T. Beuckmann, J. T. Willie, et al., “Hypothalamic orexin neurons regulate arousal according to energy balance in mice,” Neuron, vol. 38, no. 5, pp. 701–713, 2003.
- J. M. Zigman and J. K. Elmquist, “Minireview: from anorexia to obesity—the yin and yang of body weight control,” Endocrinology, vol. 144, no. 9, pp. 3749–3756, 2003.
- M. Kojima and K. Kangawa, “Drug insight: the functions of ghrelin and its potential as a multitherapeutic hormone,” Nature Clinical Practice Endocrinology and Metabolism, vol. 2, no. 2, pp. 80–88, 2006.
- C. F. Elias, C. B. Saper, E. Maratos-Flier, et al., “Chemically defined projections linking the mediobasal hypothalamus and the lateral hypothalamic area,” Journal of Comparative Neurology, vol. 402, no. 4, pp. 442–459, 1998.
- B. W. Dunlop and C. B. Nemeroff, “The role of dopamine in the pathophysiology of depression,” Archives of General Psychiatry, vol. 64, pp. 327–337, 2007.
- S. E. Hyman, R. C. Malenka, and E. J. Nestler, “Neural mechanisms of addiction: the role of reward-related learning and memory,” Annual Review of Neuroscience, vol. 29, pp. 565–598, 2006.
- V. Krishnan, M. H. Han, D. L. Graham, et al., “Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions,” Cell, vol. 131, no. 2, pp. 391–404, 2007.
- A. Abizaid, Z. W. Liu, Z. B. Andrews, et al., “Ghrelin modulates the activity and synaptic input organization of midbrain dopamine neurons while promoting appetite,” Journal of Clinical Investigation, vol. 116, no. 12, pp. 3229–3239, 2006.
- E. Jerlhag, E. Egecioglu, S. L. Dickson, A. Douhan, L. Svensson, and J. A. Engel, “Ghrelin administration into tegmental areas stimulates locomotor activity and increases extracellular concentration of dopamine in the nucleus accumbens,” Addiction Biology, vol. 12, no. 1, pp. 6–16, 2007.
- E. Jerlhag, E. Egecioglu, S. L. Dickson, M. Andersson, L. Svensson, and J. A. Engel, “Ghrelin stimulates locomotor activity and accumbal dopamine-overflow via central cholinergic systems in mice: implications for its involvement in brain reward,” Addiction Biology, vol. 11, no. 1, pp. 45–54, 2006.
- A. M. Naleid, M. K. Grace, D. E. Cummings, and A. S. Levine, “Ghrelin induces feeding in the mesolimbic reward pathway between the ventral tegmental area and the nucleus accumbens,” Peptides, vol. 26, no. 11, pp. 2274–2279, 2005.
- E. J. Nestler, M. Barrot, R. J. DiLeone, A. J. Eisch, S. J. Gold, and L. M. Monteggia, “Neurobiology of depression,” Neuron, vol. 34, no. 1, pp. 13–25, 2002.
- A. Sahay and R. Hen, “Adult hippocampal neurogenesis in depression,” Nature Neuroscience, vol. 10, no. 9, pp. 1110–1115, 2007.
- J. M. Zigman, J. E. Jones, C. E. Lee, C. B. Saper, and J. K. Elmquist, “Expression of ghrelin receptor mRNA in the rat and the mouse brain,” Journal of Comparative Neurology, vol. 494, no. 3, pp. 528–548, 2006.
- X. M. Guan, H. Yu, O. C. Palyha, et al., “Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissues,” Molecular Brain Research, vol. 48, no. 1, pp. 23–29, 1997.
- S. Diano, S. A. Farr, S. C. Benoit, et al., “Ghrelin controls hippocampal spine synapse density and memory performance,” Nature Neuroscience, vol. 9, no. 3, pp. 381–388, 2006.
- I. Johansson, S. Destefanis, N. D. Aberg, et al., “Proliferative and protective effects of growth hormone secretagogues on adult rat hippocampal progenitor cells,” Endocrinology, vol. 149, no. 5, pp. 2191–2199, 2008.
- M. Moon, S. Kim, L. Hwang, and S. Park, “Ghrelin regulates hippocampal neurogenesis in adult mice,” Endocrine Journal, vol. 56, no. 3, pp. 525–531, 2009.
- C. L. Raison, L. Capuron, and A. H. Miller, “Cytokines sing the blues: inflammation and the pathogenesis of depression,” Trends in Immunology, vol. 27, no. 1, pp. 24–31, 2006.
- R. Dantzer, J. C. O'Connor, G. G. Freund, R. W. Johnson, and K. W. Kelley, “From inflammation to sickness and depression: when the immune system subjugates the brain,” Nature Reviews Neuroscience, vol. 9, no. 1, pp. 46–56, 2008.
- S. J. Motivala, A. Sarfatti, L. Olmos, and M. R. Irwin, “Inflammatory markers and sleep disturbance in major depression,” Psychosomatic Medicine, vol. 67, no. 2, pp. 187–194, 2005.
- L. Brydon, N. A. Harrison, C. Walker, A. Steptoe, and H. D. Critchley, “Peripheral inflammation is associated with altered substantia Nigra activity and psychomotor slowing in humans,” Biological Psychiatry, vol. 63, no. 11, pp. 1022–1029, 2008.
- A. Reichenberg, R. Yirmiya, A. Schuld, et al., “Cytokine-associated emotional and cognitive disturbances in humans,” Archives of General Psychiatry, vol. 58, no. 5, pp. 445–452, 2001.
- S. Tyring, A. Gottlieb, K. Papp, et al., “Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial,” The Lancet, vol. 367, no. 9504, pp. 29–35, 2006.
- N. Hattori, T. Saito, T. Yagyu, B. H. Jiang, K. Kitagawa, and C. Inagaki, “GH, GH receptor, GH secretagogue receptor, and ghrelin expression in human T cells, B cells, and neutrophils,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 9, pp. 4284–4291, 2001.
- W. G. Li, D. Gavrila, X. Liu, et al., “Ghrelin inhibits proinflammatory responses and nuclear factor-B activation in human endothelial cells,” Circulation, vol. 109, pp. 2221–2226, 2004.
- H. Himmerich and A. J. Sheldrick, “TNF- and ghrelin: opposite effects on immune system, metabolism and mental health,” Protein & Peptide Letters. In press.
- V. D. Dixit, E. M. Schaffer, R. S. Pyle, et al., “Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells,” Journal of Clinical Investigation, vol. 114, no. 1, pp. 57–66, 2004.
- M. Granado, T. Priego, A. I. Martin, M. A. Villanua, and A. Lopez-Calderon, “Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats,” American Journal of Physiology, vol. 288, pp. E486–E492, 2005.